Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Zurich | OTHER |
| University Hospital, Zürich | OTHER |
Not provided
Not provided
Not provided
Not provided
The Global Healthcare Study on Atopic Dermatitis (GHSAD) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with atopic dermatitis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Global Healthcare Study on Atopic Dermatitis | Patients with Atopic Dermatitis |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Eczema Area and Severity Index (EASI) | Clinician-assessed measure of atopic dermatitis severity based on extent and severity of eczema signs; total score ranges from 0 to 72, with higher scores indicating more severe disease. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Measure | Description | Time Frame |
|---|---|---|
| SCORing Atopic Dermatitis (SCORAD) | Clinician-assessed measure of atopic dermatitis severity incorporating extent, intensity, and subjective symptoms; total score ranges from 0 to 103, with higher scores indicating more severe disease. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Dermatology Life Quality Index (DLQI) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patient populations across world regions seen for atopic dermatitis.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julia-Tatjana Maul, Prof. Dr. med. | Contact | +41 76 441 51 09 | julia-tatjana.maul@usz.ch | |
| Johannes Didaskalu | Contact | johannes.didaskalu@usz.ch |
| Name | Affiliation | Role |
|---|---|---|
| Julia-Tatjana Maul, Prof. Dr. med. | University of Zurich | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Zurich | Recruiting | Zurich | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003876 | Dermatitis, Atopic |
| D004485 | Eczema |
| ID | Term |
|---|---|
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
Not provided
Not provided
Not provided
Not provided
Not provided
Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment. |
| Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Patient-Oriented Eczema Measure (POEM) | Patient-reported measure of atopic dermatitis symptoms and disease burden; total score ranges from 0 to 28, with higher scores indicating more severe disease. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Peak Pruritus Numerical Rating Scale (PP-NRS) | Patient-reported assessment of peak itch severity on a numerical rating scale from 0 (no itch) to 10 (worst imaginable itch). | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Physician Global Assessment (PGA) | Clinician-assessed global measure of atopic dermatitis severity on a scale from 0 (clear) to 4 (severe). | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Body Surface Area (BSA) | Percentage of total body surface area affected by atopic dermatitis, ranging from 0% to 100%. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Patient-reported Numerical Rating Scale (NRS) for atopic dermatitis severity | Patient-reported assessment of overall atopic dermatitis severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable). | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |